Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study

详细信息    查看全文

• 作者：William Smith ; Hong Wan ; David Much ; Antoine G. Robinson…
• 刊名：Clinical Autonomic Research
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：26
• 期：4
• 页码：269-277
• 全文大小：570 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Diabetes
  Endocrinology
  Gastroenterology
  Ophthalmology
  Urology and Andrology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-1560
• 卷排序：26

文摘

ObjectiveMidodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension. The US Food and Drug Administration’s Subpart H approval, under which midodrine was initially approved, requires post-marketing studies to confirm midodrine’s clinical benefit in this indication. The purpose of this study was to evaluate the clinical benefit of midodrine with regard to symptom response.